PMC:7172841 / 757-976 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":12,"end":21},"obj":"Body_part"},{"id":"T9","span":{"begin":111,"end":117},"obj":"Body_part"},{"id":"T10","span":{"begin":128,"end":131},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma84795"}],"text":"circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-lab"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T11","span":{"begin":61,"end":77},"obj":"Disease"},{"id":"T12","span":{"begin":81,"end":90},"obj":"Disease"},{"id":"T13","span":{"begin":92,"end":100},"obj":"Disease"},{"id":"T14","span":{"begin":92,"end":96},"obj":"Disease"}],"attributes":[{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005229"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-lab"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":12,"end":21},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T9","span":{"begin":37,"end":38},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":111,"end":117},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-lab"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":132,"end":134},"obj":"Chemical"},{"id":"T6","span":{"begin":186,"end":188},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A7","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-lab"}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T5","span":{"begin":71,"end":77},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0100806"}],"text":"circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-lab"}

    LitCovid-PMC-OGER-BB

    {"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T26","span":{"begin":0,"end":11},"obj":"CL:0000080"},{"id":"T27","span":{"begin":12,"end":21},"obj":"CL:0000576"},{"id":"T28","span":{"begin":61,"end":70},"obj":"NCBITaxon:2"},{"id":"T29","span":{"begin":92,"end":102},"obj":"SP_7"},{"id":"T30","span":{"begin":111,"end":117},"obj":"UBERON:0001969"},{"id":"T31","span":{"begin":128,"end":131},"obj":"PR:000029150"},{"id":"T32","span":{"begin":135,"end":145},"obj":"GO:0010467"},{"id":"T33","span":{"begin":186,"end":190},"obj":"PR:000001393"},{"id":"T34","span":{"begin":199,"end":210},"obj":"DG_35"},{"id":"T7633","span":{"begin":0,"end":11},"obj":"CL:0000080"},{"id":"T99503","span":{"begin":12,"end":21},"obj":"CL:0000576"},{"id":"T38740","span":{"begin":61,"end":70},"obj":"NCBITaxon:2"},{"id":"T85947","span":{"begin":92,"end":102},"obj":"SP_7"},{"id":"T29939","span":{"begin":111,"end":117},"obj":"UBERON:0001969"},{"id":"T8998","span":{"begin":128,"end":131},"obj":"PR:000029150"},{"id":"T62491","span":{"begin":135,"end":145},"obj":"GO:0010467"},{"id":"T78149","span":{"begin":186,"end":190},"obj":"PR:000001393"},{"id":"T18501","span":{"begin":199,"end":210},"obj":"DG_35"}],"text":"circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-lab"}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"42","span":{"begin":186,"end":190},"obj":"Gene"},{"id":"46","span":{"begin":92,"end":102},"obj":"Species"},{"id":"47","span":{"begin":103,"end":110},"obj":"Species"},{"id":"49","span":{"begin":81,"end":90},"obj":"Species"},{"id":"51","span":{"begin":199,"end":210},"obj":"Chemical"},{"id":"62","span":{"begin":71,"end":77},"obj":"Disease"}],"attributes":[{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"Gene:3569"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:2697049"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Tax:9606"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:11309"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:C502936"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D018805"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-lab"}